Shu‐Chen Kuo

5.0k total citations
168 papers, 3.8k citations indexed

About

Shu‐Chen Kuo is a scholar working on Molecular Medicine, Epidemiology and Endocrinology. According to data from OpenAlex, Shu‐Chen Kuo has authored 168 papers receiving a total of 3.8k indexed citations (citations by other indexed papers that have themselves been cited), including 84 papers in Molecular Medicine, 75 papers in Epidemiology and 43 papers in Endocrinology. Recurrent topics in Shu‐Chen Kuo's work include Antibiotic Resistance in Bacteria (84 papers), Vibrio bacteria research studies (26 papers) and Antibiotics Pharmacokinetics and Efficacy (25 papers). Shu‐Chen Kuo is often cited by papers focused on Antibiotic Resistance in Bacteria (84 papers), Vibrio bacteria research studies (26 papers) and Antibiotics Pharmacokinetics and Efficacy (25 papers). Shu‐Chen Kuo collaborates with scholars based in Taiwan, United States and Japan. Shu‐Chen Kuo's co-authors include Te-Li Chen, Yi‐Tzu Lee, Chang‐Phone Fung, Yung‐Tai Chen, Shuo‐Ming Ou, Chia-Jen Shih, Pei-Wen Chao, Szu‐Yuan Li, Yi-Jung Lee and Ya‐Sung Yang and has published in prestigious journals such as Angewandte Chemie International Edition, Circulation and Nano Letters.

In The Last Decade

Shu‐Chen Kuo

159 papers receiving 3.7k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Shu‐Chen Kuo Taiwan	36	1.8k	1.3k	805	749	558	168	3.8k
Anastasia Antoniadou Greece	34	1.8k 1.0×	1.3k 1.0×	415 0.5×	281 0.4×	1.1k 1.9×	124	3.7k
Adrian Brink South Africa	32	1.6k 0.9×	956 0.7×	478 0.6×	324 0.4×	554 1.0×	122	3.4k
Garyphallia Poulakou Greece	33	1.7k 0.9×	1.3k 1.0×	351 0.4×	359 0.5×	892 1.6×	106	3.9k
Emanuele Durante‐Mangoni Italy	35	1.2k 0.7×	2.3k 1.8×	261 0.3×	376 0.5×	1.2k 2.2×	145	4.3k
Jean‐Ralph Zahar France	38	1.1k 0.6×	2.1k 1.6×	362 0.4×	441 0.6×	1.5k 2.7×	154	5.1k
Francesco Giuseppe De Rosa Italy	36	1.6k 0.9×	2.0k 1.5×	304 0.4×	448 0.6×	1.7k 3.0×	285	5.7k
Thomas Gottlieb Australia	29	734 0.4×	1.0k 0.8×	341 0.4×	426 0.6×	1.3k 2.3×	113	3.0k
Argyris Michalopoulos Greece	42	2.9k 1.6×	2.7k 2.1×	456 0.6×	509 0.7×	1.0k 1.9×	99	6.2k
Dafna Yahav Israel	41	1.3k 0.7×	1.8k 1.4×	218 0.3×	516 0.7×	1.6k 2.8×	207	5.5k
Larry H. Danziger United States	41	1.4k 0.8×	1.9k 1.4×	274 0.3×	706 0.9×	1.2k 2.1×	153	5.4k

Countries citing papers authored by Shu‐Chen Kuo

Since Specialization

Citations

This map shows the geographic impact of Shu‐Chen Kuo's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Shu‐Chen Kuo with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Shu‐Chen Kuo more than expected).

Fields of papers citing papers by Shu‐Chen Kuo

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Shu‐Chen Kuo. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Shu‐Chen Kuo. The network helps show where Shu‐Chen Kuo may publish in the future.

Co-authorship network of co-authors of Shu‐Chen Kuo

This figure shows the co-authorship network connecting the top 25 collaborators of Shu‐Chen Kuo. A scholar is included among the top collaborators of Shu‐Chen Kuo based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Shu‐Chen Kuo. Shu‐Chen Kuo is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Wang, Yanru, Yu-Lin Lee, I‐Wen Huang, et al.. (2025). Susceptibilities of cefiderocol, meropenem-xeruborbactam, cefepime-taniborbactam, aztreonam-avibactam, and sulbactam-durlobactam against imipenem-non-susceptible Gram-negative bacilli in Taiwan. International Journal of Infectious Diseases. 163. 108279–108279.

Kuo, Shu‐Chen, Ya‐Ting Hsu, Yi‐Kai Chen, et al.. (2025). Excess Mortality and Containment Performance During the COVID-19 Pandemic: Evidence From 34 Countries. American Journal of Public Health. 115(9). 1518–1528.

Lee, Yu-Lin, Yih‐Ru Shiau, Huiying Wang, et al.. (2025). In vitro activity of cefepime-zidebactam, ceftolozane-tazobactam, ceftazidime-avibactam, imipenem-relebactam, and other comparators against imipenem-non-susceptible Pseudomonas aeruginosa in Taiwan, 2022. International Journal of Antimicrobial Agents. 66(3). 107550–107550. 1 indexed citations

Lee, Yu-Lin, Chun-Eng Liu, Yih‐Ru Shiau, et al.. (2025). Antimicrobial resistance among imipenem-non-susceptible Escherichia coli and Klebsiella pneumoniae isolates, with an emphasis on novel β-lactam/β-lactamase inhibitor combinations and tetracycline derivatives: The Taiwan surveillance of antimicrobial resistance program, 2020–2022. Journal of Microbiology Immunology and Infection. 58(2). 219–225. 3 indexed citations

Lee, Yi‐Tzu, Jun‐Ren Sun, Li-Hua Li, et al.. (2025). Comparison of clinical manifestations, antimicrobial susceptibility patterns, and carbapenem resistance determinants between Acinetobacter seifertii and Acinetobacter nosocomialis isolated in Taiwan. Journal of Microbiology Immunology and Infection.

Wu, Han‐Chieh, Hung‐Wei Cheng, Shu‐Chen Kuo, et al.. (2025). Streamlining whole genome sequencing for clinical diagnostics with ONT technology. Scientific Reports. 15(1). 6270–6270. 4 indexed citations

Yang, Ya‐Sung, Hsing‐Yu Chen, Wei‐Yao Wang, et al.. (2024). Imipenem reduces the efficacy of vancomycin against Elizabethkingia species. Journal of Antimicrobial Chemotherapy. 79(8). 2048–2052. 1 indexed citations

Kuo, Shu‐Chen, et al.. (2024). Changing epidemiology and antimicrobial resistance of bacteria causing bacteremia in Taiwan: 2002–2020. Microbiology Spectrum. 12(8). e0060824–e0060824. 1 indexed citations

Yang, Ya‐Sung, Yu-Lin Lee, Yuag-Meng Liu, et al.. (2024). Acquired blaCfxA-3 carried by a conjugative transposon or duplicated intrinsic blaCME-3 mediates cefiderocol resistance in Elizabethkingia anophelis clinical isolates. International Journal of Antimicrobial Agents. 64(6). 107378–107378.

10.

Chen, Feng-Jui, et al.. (2024). Clonal expansion of Tn1546-like transposon-carrying vancomycin-resistant Enterococcus faecium, a nationwide study in Taiwan, 2004-2018. Journal of Global Antimicrobial Resistance. 39. 100–108. 3 indexed citations

11.

Huang, Wei‐Cheng, Shu-Yuan Hsu, Huiying Wang, et al.. (2023). In vitro and in vivo evidence discourages routine testing and reporting of piperacillin/tazobactam susceptibility of Elizabethkingia species. Journal of Antimicrobial Chemotherapy. 79(1). 200–202. 5 indexed citations

12.

Lai, Jui‐Fen, Chi‐Jung Wu, Iwen Huang, et al.. (2023). High-level levofloxacin-resistant emm12 group A Streptococcus, 2012–2018: A multicenter study in Taiwan. Journal of Microbiology Immunology and Infection. 56(4). 875–879. 3 indexed citations

13.

Kuo, Shu‐Chen, Ya‐Ting Hsu, Chao A. Hsiung, et al.. (2022). Contribution of Testing Strategies and Contact Tracing towards COVID-19 Outbreaks Control: A Mathematical Modeling Study. Tropical Medicine and Infectious Disease. 7(11). 376–376.

14.

Kuo, Shu‐Chen, Chien‐Feng Li, Chao A. Hsiung, et al.. (2022). Discrimination of Methicillin-resistant Staphylococcus aureus by MALDI-TOF Mass Spectrometry with Machine Learning Techniques in Patients with Staphylococcus aureus Bacteremia. Pathogens. 11(5). 586–586. 8 indexed citations

15.

Lin, Ching‐Hsiung, Shu‐Chen Kuo, Ming‐Chia Hsieh, et al.. (2019). Effect of diabetes mellitus on risk of latent TB infection in a high TB incidence area: a community-based study in Taiwan. BMJ Open. 9(10). e029948–e029948. 21 indexed citations

16.

Yang, Ya‐Sung, Yu‐Ching Chou, Cherng‐Lih Perng, et al.. (2018). Overexpression of AdeABC efflux pump associated with tigecycline resistance in clinical Acinetobacter nosocomialis isolates. Clinical Microbiology and Infection. 25(4). 512.e1–512.e6. 39 indexed citations

17.

Shih, Chia‐Jen, Yung‐Tai Chen, Shuo‐Ming Ou, et al.. (2016). Adverse Effects of Oral Nonselective and cyclooxygenase-2-Selective NSAIDs on Hospitalization for Acute Kidney Injury. Medicine. 95(9). e2645–e2645. 33 indexed citations

18.

Shih, Chia-Jen, Hung‐Ta Chen, Pei-Wen Chao, et al.. (2015). Angiotensin-converting enzyme inhibitors, angiotensin II receptor blockers and the risk of major adverse cardiac events in patients with diabetes and prior stroke. Journal of Hypertension. 34(3). 567–575. 7 indexed citations

19.

Shih, Chia-Jen, Yueh-Lin Wu, Shu‐Chen Kuo, et al.. (2015). Association of Hypoglycemia With Incident Chronic Kidney Disease in Patients With Type 2 Diabetes. Medicine. 94(16). e771–e771. 12 indexed citations

20.

Kuo, Shu‐Chen, et al.. (2012). Evaluation of the effect of appropriate antimicrobial therapy on mortality associated with Acinetobacter nosocomialis bacteraemia. Clinical Microbiology and Infection. 19(7). 634–639. 19 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact